Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Summary

The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3 mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection.

Timeline

Start

2011-11

Primary completion

2014-05

Completion

2014-05

Drugs

Indications